Veradermics (NYSE: MANE), a pharmaceutical company specializing in skin therapies, is up 268% since its initial public offering (IPO) on Feb. 4. The late-stage clinical healthcare company's lead therapy, VDPHL01, could be the first non-hormonal oral therapeutic for pattern hair loss. On the plus side, VDPHL01 could soon be headed to approval by the Food and Drug Administration (FDA). On the downside, the company isn't profitable and only has one drug in its pipeline. Here are three reasons why the stock may still have more upside.
CryptoAlerta — análise de criptomoedas e mercado em tempo real